Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of Azenosertib (ZN-c3) in women with recurrent or persistent uterine serous carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Serous Carcinoma

Drugs mentioned

• Azenosertib (azenosertib)

Snippet

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Conditions: Uterine Serous Carcinoma | Phase 2 | Status: COMPLETED